Aurinia Pharmaceuticals (NASDAQ:AUPH) has announced that the first participant has been dosed in its Phase 1a study of AUR200, a differentiated, best-in-class potential therapy for autoimmune diseases targeting B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL). The study data is expected in the first half of 2025.
The single ascending dose study will assess the safety, tolerability, pharmacokinetics, and changes in biomarkers of AUR200 in healthy volunteers.
In a statement, Greg Keenan, M.S., CMO of Aurinia, said, “The start of the single ascending dose study is an important milestone for developing AUR200, which has the potential to serve as a best-in-class treatment in autoimmune diseases with high unmet need. We believe AUR200 is a more potent compound with a higher binding affinity compared to the two other TACI-Fc molecules designed to bind both BAFF and APRIL that were tested in our preclinical research. We expect the data from this early-stage study to provide key points of differentiation that will inform further clinical development efforts.”
